Back to results
US 12,740,986 B2Granted
Histone deacetylase inhibitors for use in immunotherapy
AssigneeViracta Subsidiary, Inc.
InventorJames N. Woody
Life of this patent
Estimating the term…
Abstract
Provided are methods and compositions for the treatment of cancer. The methods comprise administering to a subject an HDAC inhibitor and an immunotherapeutic. In certain instances the immunotherapeutic is a chimeric antigen receptor T cell, an antibody or polypeptide that binds a checkpoint inhibitor, or a vaccine.
Claims9
A method for treating colorectal carcinoma in an individual in need thereof comprising administering to the individual afflicted with colorectal carcinoma a therapeutically effective amount of:
- a) an HDAC inhibitor, wherein the HDAC inhibitor comprises (2-(6-{[(6-Fluoroquinolin-2-yl)methyl]amino}-3-azabicyclo[3.1.0]hex-3-yl)-N-hydroxypyrimidine-5-carboxamide);
- and
- b) an anti-PD-1 antibody or antigen binding fragment thereof.
Dependencies are inferred from the claim text.